Erasca will present preliminary clinical data and future directions for its lead clinical candidates with best-in-class potential, ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601, for the treatment of advanced solid tumors with RAS/MAPK alterations.

Key Opinion Leader (KOL) David S. Hong, MD, of MD Anderson Cancer Center will provide an overview of the current treatment landscape and therapeutic opportunities in cancers driven by the RAS/MAPK pathway and will discuss Erasca’s lead programs in this context.

A live question and answer session will follow.